Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammopharmacology

27-04-2024 | Myocardial Infarction | Review

IL-1 signaling pathway, an important target for inflammation surrounding in myocardial infarction

Authors: Jianwu Huang, Wenlong Kuang, Zihua Zhou

Published in: Inflammopharmacology

Login to get access

Abstract

Acute myocardial infarction is an important cardiovascular disease worldwide. Although the mortality rate of myocardial infarction (MI) has improved dramatically in recent years due to timely treatment, adverse remodeling of the left ventricle continues to affect cardiac function. Various immune cells are involved in this process to induce inflammation and amplification. The infiltration of inflammatory cells in the infarcted myocardium is induced by various cytokines and chemokines, and the recruitment of leukocytes further amplifies the inflammatory response. As an increasing number of clinical anti-inflammatory therapies have achieved significant success in recent years, treating myocardial infarction by targeting inflammation may become a novel therapeutic option. In particular, successful clinical trials of canakinumab have demonstrated the important role of the inflammatory factor interleukin-1 (IL-1) in atherosclerosis. Targeted IL-1 therapy may decrease inflammation levels and improve cardiac function in patients after myocardial infarction. This article reviews the complex series of responses after myocardial infarction, including the involvement of inflammatory cells and the role of cytokines and chemokines, focusing on the progression of the IL-1 family in myocardial infarction as well as the performance of current targeted therapy drugs in experiments.
Literature
Abbate A, Salloum FN, Van Tassell BW, Vecile E, Toldo S, Seropian I, Mezzaroma E, Dobrina A (2011) Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS ONE 6:e27923PubMedPubMedCentralCrossRef
Abbate A, Trankle CR, Buckley LF, Lipinski MJ, Appleton D, Kadariya D, Canada JM, Carbone S, Roberts CS, Abouzaki N et al (2020) Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction. J Am Heart Assoc 9:e014941PubMedPubMedCentralCrossRef
Abbate A, Wohlford GF, Del Buono MG, Chiabrando JG, Markley R, Turlington J, Kadariya D, Trankle CR, Biondi-Zoccai G, Lipinski MJ et al (2022) Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. Eur Heart J Cardiovasc Pharmacother 8:503–510PubMedCrossRef
Adamo L, Staloch LJ, Rocha-Resende C, Matkovich SJ, Jiang W, Bajpai G, Weinheimer CJ, Kovacs A, Schilling JD, Barger PM, et al (2018) Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury. JCI Insight 3
Aksentijevich I, Kastner DL (2011) Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol 7:469–478PubMedCrossRef
Bageghni SA, Hemmings KE, Yuldasheva NY, Maqbool A, Gamboa-Esteves FO, Humphreys NE, Jackson MS, Denton CP, Francis S, Porter KE, et al (2019) Fibroblast-specific deletion of interleukin-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction. JCI Insight 5
Bajpai G, Bredemeyer A, Li W, Zaitsev K, Koenig AL, Lokshina I, Mohan J, Ivey B, Hsiao HM, Weinheimer C et al (2019) Tissue resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. Circ Res 124:263–278PubMedPubMedCentralCrossRef
Befekadu R, Grenegård M, Larsson A, Christensen K, Ramström S (2022) Levels of soluble tumor necrosis factor receptor 1 and 2 are associated with survival after ST segment elevation myocardial infarction. Sci Rep 12:14762PubMedPubMedCentralCrossRef
Bettiol A, Silvestri E, Di Scala G, Amedei A, Becatti M, Fiorillo C, Lopalco G, Salvarani C, Cantarini L, Soriano A et al (2019) The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review. Rheumatol Int 39:971–990PubMedCrossRef
Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA Jr (1985) Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion. Am J Pathol 121:394–403PubMedPubMedCentral
Blanco-Domínguez R, de la Fuente H, Rodríguez C, Martín-Aguado L, Sánchez-Díaz R, Jiménez-Alejandre R, Rodríguez-Arabaolaza I, Curtabbi A, García-Guimaraes MM, Vera A, et al (2022) CD69 expression on regulatory T cells protects from immune damage after myocardial infarction. J Clin Invest 132
Blech M, Peter D, Fischer P, Bauer MM, Hafner M, Zeeb M, Nar H (2013) One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β. J Mol Biol 425:94–111PubMedCrossRef
Bonaventura A, Vecchié A, Abbate A, Montecucco F (2020) Neutrophil extracellular traps and cardiovascular diseases: an update. Cells 9
Brikos C, Wait R, Begum S, O’Neill LA, Saklatvala J (2007) Mass spectrometric analysis of the endogenous type I interleukin-1 (IL-1) receptor signaling complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 as the stable components. Mol Cell Proteom MCP 6:1551–1559PubMedCrossRef
Buckley LF, Abbate A (2018) Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J 39:2063–2069PubMedCrossRef
Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A, Frangogiannis NG (2008) Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 173:57–67PubMedPubMedCentralCrossRef
Cai S, Zhao M, Zhou B, Yoshii A, Bugg D, Villet O, Sahu A, Olson GS, Davis J, Tian R (2023) Mitochondrial dysfunction in macrophages promotes inflammation and suppresses repair after myocardial infarction. J Clin Invest 133
Cao Z, Henzel WJ, Gao X (1996) IRAK: a kinase associated with the interleukin-1 receptor. Science (new York, NY) 271:1128–1131CrossRef
Carbone F, Nencioni A, Mach F, Vuilleumier N, Montecucco F (2013) Pathophysiological role of neutrophils in acute myocardial infarction. Thromb Haemost 110:501–514PubMedCrossRef
Casadio R, Frigimelica E, Bossù P, Neumann D, Martin MU, Tagliabue A, Boraschi D (2001) Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1beta/IL-1R(I) complex. FEBS Lett 499:65–68PubMedCrossRef
Chen C, Feng Y, Zou L, Wang L, Chen HH, Cai JY, Xu JM, Sosnovik DE, Chao W (2014) Role of extracellular RNA and TLR3-Trif signaling in myocardial ischemia-reperfusion injury. J Am Heart Assoc 3:e000683PubMedPubMedCentralCrossRef
Chen X, Li Y, Li J, Liu T, Jiang Q, Hong Y, Wang Q, Li C, Guo D, Wang Y (2022) Qishen granule (QSG) exerts cardioprotective effects by inhibiting NLRP3 inflammasome and pyroptosis in myocardial infarction rats. J Ethnopharmacol 285:114841PubMedCrossRef
Chen C, Wang J, Liu C, Hu J (2023) Cardiac resident macrophages: key regulatory mediators in the aftermath of myocardial infarction. Front Immunol 14:1207100PubMedPubMedCentralCrossRef
Colantuoni M, Jofra Hernandez R, Pettinato E, Basso-Ricci L, Magnani L, Andolfi G, Rigamonti C, Finardi A, Romeo V, Soldi M, et al (2023) Constitutive IL-1RA production by modified immune cells protects against IL-1-mediated inflammatory disorders. Sci Transl Med 15:eade3856
Collins KH, Pferdehirt L, Saleh LS, Savadipour A, Springer LE, Lenz KL, Thompson DM Jr, Oswald SJ, Pham CTN, Guilak F (2023) Hydrogel encapsulation of genome-engineered stem cells for long-term self-regulating anti-cytokine therapy. Gels (Basel, Switzerland) 9
Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, Giri JG, Dower SK, Sims JE, Mantovani A (1993) Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science (new York, NY) 261:472–475CrossRef
Davidson SM, Ferdinandy P, Andreadou I, Bøtker HE, Heusch G, Ibáñez B, Ovize M, Schulz R, Yellon DM, Hausenloy DJ et al (2019) Multitarget strategies to reduce myocardial ischemia/reperfusion injury: JACC review topic of the week. J Am Coll Cardiol 73:89–99PubMedCrossRef
Del Buono MG, Damonte JI, Chiabrando JG, Markley R, Turlington J, Trankle CR, Kang L, Biondi-Zoccai G, Van Tassell BW, Abbate A (2022a) Effect of IL-1 blockade with Anakinra on heart failure outcomes in patients with anterior versus nonanterior ST elevation myocardial infarction. J Cardiovasc Pharmacol 79:774–780PubMedPubMedCentralCrossRef
Del Buono MG, Damonte JI, Trankle CR, Kadariya D, Carbone S, Thomas G, Turlington J, Markley R, Canada JM, Biondi-Zoccai GG et al (2022b) Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction. Sci Rep 12:1254PubMedPubMedCentralCrossRef
Del Buono MG, Damonte JI, Moroni F, Chiabrando JG, Markley R, Turlington J, Trankle CR, Kang L, Biondi-Zoccai G, Kontos MC et al (2023) Clinical and pharmacological implications of time to treatment with interleukin-1 blockade in ST-segment elevation myocardial infarction. J Pharmacol Exp Ther 386:156–163PubMedCrossRef
Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, Michael LH, Rollins BJ, Entman ML, Frangogiannis NG (2005) CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 96:881–889PubMedCrossRef
Ding HS, Huang Y, Qu JF, Wang YJ, Huang ZY, Wang FY, Yi WJ, Liu XX (2023) Panaxynol ameliorates cardiac ischemia/reperfusion injury by suppressing NLRP3-induced pyroptosis and apoptosis via HMGB1/TLR4/NF-κB axis. Int Immunopharmacol 121:110222PubMedCrossRef
Diwanji R, O’Brien NA, Choi JE, Nguyen B, Laszewski T, Grauel AL, Yan Z, Xu X, Wu J, Ruddy DA et al (2023) Targeting the IL1β pathway for cancer immunotherapy remodels the tumor microenvironment and enhances antitumor immune responses. Cancer Immunol Res 11:777–791PubMedCrossRef
Duerschmied D, Suidan GL, Demers M, Herr N, Carbo C, Brill A, Cifuni SM, Mauler M, Cicko S, Bader M et al (2013) Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 121:1008–1015PubMedPubMedCentralCrossRef
El Sayed H, Kerensky R, Stecher M, Mohanty P, Davies M (2016) A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularization. J Vasc Surg 63:133-141.e131PubMedCrossRef
Emran T, Chowdhury NI, Sarker M, Bepari AK, Hossain M, Rahman GMS, Reza HM (2021) L-carnitine protects cardiac damage by reducing oxidative stress and inflammatory response via inhibition of tumor necrosis factor-alpha and interleukin-1beta against isoproterenol-induced myocardial infarction. Biomed Pharmacother 143:112139
Enzan N, Matsushima S, Ikeda S, Okabe K, Ishikita A, Yamamoto T, Sada M, Miyake R, Tsutsui Y, Nishimura R et al (2023) ZBP1 protects against mtDNA-induced myocardial inflammation in failing hearts. Circ Res 132:1110–1126PubMedPubMedCentralCrossRef
Fan Q, Tao R, Zhang H, Xie H, Lu L, Wang T, Su M, Hu J, Zhang Q, Chen Q et al (2019) Dectin-1 contributes to myocardial ischemia/reperfusion injury by regulating macrophage polarization and neutrophil infiltration. Circulation 139:663–678PubMedCrossRef
Feng G, Bajpai G, Ma P, Koenig A, Bredemeyer A, Lokshina I, Lai L, Förster I, Leuschner F, Kreisel D et al (2022) CCL17 Aggravates myocardial injury by suppressing recruitment of regulatory T cells. Circulation 145:765–782PubMedPubMedCentralCrossRef
Frangogiannis NG, Lindsey ML, Michael LH, Youker KA, Bressler RB, Mendoza LH, Spengler RN, Smith CW, Entman ML (1998) Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation 98:699–710PubMedCrossRef
Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD (2010) Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 107:15880–15885PubMedPubMedCentralCrossRef
Gao R, Shi H, Chang S, Gao Y, Li X, Lv C, Yang H, Xiang H, Yang J, Xu L et al (2019) The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. Int Immunopharmacol 74:105575PubMedCrossRef
Gao RF, Li X, Xiang HY, Yang H, Lv CY, Sun XL, Chen HZ, Gao Y, Yang JS, Luo W et al (2021) The covalent NLRP3-inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice. Int Immunopharmacol 90:107133PubMedCrossRef
Garon EB, Chih-Hsin Yang J, Dubinett SM (2020) The role of interleukin 1β in the pathogenesis of lung cancer. JTO Clin Res Reports 1:100001CrossRef
Gilmore TD (1999) The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 18:6842–6844PubMedCrossRef
Gottlieb A, Natsis NE, Kerdel F, Forman S, Gonzalez E, Jimenez G, Hernandez L, Kaffenberger J, Guido G, Lucas K et al (2020) A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain. J Invest Dermatol 140:1538-1545.e1532PubMedCrossRef
Gu J, Shi JZ, Wang YX, Liu L, Wang SB, Sun JT, Shan TK, Wang H, Wang QM, Wang LS (2022) LncRNA FAF attenuates hypoxia/ischaemia-induced pyroptosis via the miR-185-5p/PAK2 axis in cardiomyocytes. J Cell Mol Med 26:2895–2907PubMedPubMedCentralCrossRef
Guo J, Hu Z, Ren L, Zhao W, Zuo R, Guo S, Jia C, Gao W (2023) Circulating tumor necrosis factor-α, interleukin-1β, and interleukin-17A estimates increased major adverse cardiac event risk in acute myocardial infarction patients. J Clin Lab Anal 37:e24853PubMedPubMedCentralCrossRef
Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, Prabhu SD (2009) Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation 119:1386–1397PubMedPubMedCentralCrossRef
Han X, Yang Y, Zhang M, Li L, Xue Y, Jia Q, Wang X, Guan S (2022) Liquiritin protects against cardiac fibrosis after myocardial infarction by inhibiting CCL5 expression and the NF-κB signaling pathway. Drug Des Dev Ther 16:4111–4125CrossRef
Handa M, Vanegas S, Maddux BA, Mendoza N, Zhu S, Goldfine ID, Mirza AM (2013) XOMA 052, an anti-IL-1β monoclonal antibody, prevents IL-1β-mediated insulin resistance in 3T3-L1 adipocytes. Obesity (silver Spring, MD) 21:306–309PubMedCrossRef
Harouki N, Nicol L, Remy-Jouet I, Henry JP, Dumesnil A, Lejeune A, Renet S, Golding F, Djerada Z, Wecker D et al (2017) The IL-1β antibody gevokizumab limits cardiac remodeling and coronary dysfunction in rats with heart failure. JACC Basic Transl Sci 2:418–430PubMedPubMedCentralCrossRef
Hartikainen TS, Sörensen NA, Haller PM, Goßling A, Lehmacher J, Zeller T, Blankenberg S, Westermann D, Neumann JT (2020) Clinical application of the 4th Universal Definition of Myocardial Infarction. Eur Heart J 41:2209–2216PubMedCrossRef
Hettwer J, Hinterdobler J, Miritsch B, Deutsch MA, Li X, Mauersberger C, Moggio A, Braster Q, Gram H, Robertson AAB et al (2022) Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis. Cardiovasc Res 118:2778–2791PubMedCrossRef
Hu Q, Shi H, Zeng T, Liu H, Su Y, Cheng X, Ye J, Yin Y, Liu M, Zheng H et al (2019) Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still’s disease. Arthritis Res Ther 21:9PubMedPubMedCentralCrossRef
Huang J, Li Y, Jiang Z, Wu L, Liu Y, Ma S, Li L, Wang H (2022) IL-1β promotes hypoxic vascular endothelial cell proliferation through the miR-24–3p/NKAP/NF-κB axis. Biosci Reports 42
Huse C, Anstensrud AK, Michelsen AE, Ueland T, Broch K, Woxholt S, Yang K, Sharma K, Tøllefsen IM, Bendz B et al (2022) Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial. EBioMedicine 80:104013PubMedPubMedCentralCrossRef
Ikeda G, Matoba T, Ishikita A, Nagaoka K, Nakano K, Koga JI, Tsutsui H, Egashira K (2021) Nanoparticle-mediated simultaneous targeting of mitochondrial injury and inflammation attenuates myocardial ischemia-reperfusion injury. J Am Heart Assoc 10:e019521PubMedPubMedCentralCrossRef
Isoda K, Kamezawa Y, Tada N, Sato M, Ohsuzu F (2001) Myocardial hypertrophy in transgenic mice overexpressing human interleukin 1alpha. J Cardiac Fail 7:355–364CrossRef
Javan H, Li L, Schaaf CL, Lee YS, Salama ME, Dinarello CA, Selzman CH (2022) Interleukin-1 receptor antagonism abrogates acute pressure overload-induced murine heart failure. Ann Thorac Surg 114:98–107PubMedCrossRef
Karshovska E, Weber C, von Hundelshausen P (2013) Platelet chemokines in health and disease. Thromb Haemost 110:894–902PubMedCrossRef
Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet (london, England) 361:13–20PubMedCrossRef
Khandagale A, Lindahl B, Lind SB, Shevchenko G, Siegbahn A, Christersson C (2022) Plasma-derived extracellular vesicles from myocardial infarction patients inhibits tumor necrosis factor-alpha induced cardiac cell death. Curr Res Transl Med 70:103323PubMedCrossRef
Kim ND, Luster AD (2013) To B or not to B–that is the question for myocardial infarction. Nat Med 19:1208–1210PubMedCrossRef
Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, Insalaco A, LeWinter M, Lewis BS, Lin D et al (2021) Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med 384:31–41PubMedCrossRef
Kurt-Jones EA, Beller DI, Mizel SB, Unanue ER (1985) Identification of a membrane-associated interleukin 1 in macrophages. Proc Natl Acad Sci USA 82:1204–1208PubMedPubMedCentralCrossRef
Kurzrock R, Hickish T, Wyrwicz L, Saunders M, Wu Q, Stecher M, Mohanty P, Dinarello CA, Simard J (2019) Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer. Oncoimmunology 8:1551651PubMedCrossRef
Lacey CA, Mitchell WJ, Dadelahi AS, Skyberg JA (2018) Caspase-1 and Caspase-11 mediate pyroptosis, inflammation, and control of brucella joint infection. Infect Immun 86
Landmann EC, Walker UA (2017) Pharmacological treatment options for cryopyrin-associated periodic syndromes. Expert Rev Clin Pharmacol 10:855–864PubMedCrossRef
Laura BC, Morales-Maldonado MA, Rodgers A, Kitt LA, Humphry M, Figg N, Bennett MR, Clarke MCH (2023) Thrombin activated Interleukin-1α drives atherogenesis, but also promotes VSMC proliferation and collagen production. Cardiovasc Res
Lee CC, Chen WT, Chen SY, Lee TM (2021) Taurine alleviates sympathetic innervation by inhibiting NLRP3 inflammasome in postinfarcted rats. J Cardiovasc Pharmacol 77:745–755PubMedPubMedCentralCrossRef
Lei Z, Luan F, Zhang X, Peng L, Li B, Peng X, Liu Y, Liu R, Zeng N (2022) Piperazine ferulate protects against cardiac ischemia/reperfusion injury in rat via the suppression of NLRP3 inflammasome activation and pyroptosis. Eur J Pharmacol 920:174856PubMedCrossRef
Li A, Yu Y, Ding X, Qin Y, Jiang Y, Wang X, Liu G, Chen X, Yue E, Sun X et al (2020) MiR-135b protects cardiomyocytes from infarction through restraining the NLRP3/caspase-1/IL-1β pathway. Int J Cardiol 307:137–145PubMedCrossRef
Li Y, Tu Z, Chen F, Yang X, Deng R, Su F, Cheng Z, Li S, Ong SB, Wang D et al (2023b) Anti-inflammatory effect of Danhong injection through inhibition of GSDMD-mediated pyroptosis. Phytomed Int J Phytother Phytopharmacol 113:154743
Li L, Cao J, Li S, Cui T, Ni J, Zhang H, Zhu Y, Mao J, Gao X, Midgley AC, et al (2023a) M2 macrophage-derived sEV regulate pro-inflammatory CCR2(+) macrophage subpopulations to favor post-AMI cardiac repair. Adv Sci (Weinheim, Baden-Wurttemberg, Germany) 10:e2202964
Liberale L, Carbone F, Camici GG, Montecucco F (2019) IL-1β and statin treatment in patients with myocardial infarction and diabetic cardiomyopathy. J Clin Med 8
Lin J, Li Q, Jin T, Wang J, Gong Y, Lv Q, Wang M, Chen J, Shang M, Zhao Y et al (2022) Cardiomyocyte IL-1R2 protects heart from ischemia/reperfusion injury by attenuating IL-17RA-mediated cardiomyocyte apoptosis. Cell Death Dis 13:90PubMedPubMedCentralCrossRef
Liu H, Huang Y, Zhao Y, Kang GJ, Feng F, Wang X, Liu M, Shi G, Revelo X, Bernlohr D et al (2023) Inflammatory macrophage interleukin-1β mediates high-fat diet-induced heart failure with preserved ejection fraction. JACC Basic Transl Sci 8:174–185PubMedCrossRef
Lugrin J, Parapanov R, Milano G, Cavin S, Debonneville A, Krueger T, Liaudet L (2023) The systemic deletion of interleukin-1α reduces myocardial inflammation and attenuates ventricular remodeling in murine myocardial infarction. Sci Rep 13:4006PubMedPubMedCentralCrossRef
Lugrin J, Parapanov R, Rosenblatt-Velin N, Rignault-Clerc S, Feihl F, Waeber B, Müller O, Vergely C, Zeller M, Tardivel A, et al (2015) Cutting edge: IL-1α is a crucial danger signal triggering acute myocardial inflammation during myocardial infarction. J Immunol (Baltimore, MD: 1950) 194:499–503
Lyu J, Wang M, Kang X, Xu H, Cao Z, Yu T, Huang K, Wu J, Wei X, Lei Q (2020) Macrophage-mediated regulation of catecholamines in sympathetic neural remodeling after myocardial infarction. Basic Res Cardiol 115:56PubMedCrossRef
Ma Y, Yabluchanskiy A, Lindsey ML (2013) Neutrophil roles in left ventricular remodeling following myocardial infarction. Fibrogene Tissue Repair 6:11CrossRef
Ma Y, Yabluchanskiy A, Iyer RP, Cannon PL, Flynn ER, Jung M, Henry J, Cates CA, Deleon-Pennell KY, Lindsey ML (2016) Temporal neutrophil polarization following myocardial infarction. Cardiovasc Res 110:51–61PubMedPubMedCentralCrossRef
Maekawa N, Wada H, Kanda T, Niwa T, Yamada Y, Saito K, Fujiwara H, Sekikawa K, Seishima M (2002) Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-alpha. J Am Coll Cardiol 39:1229–1235PubMedCrossRef
Malinowsky D, Lundkvist J, Layé S, Bartfai T (1998) Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett 429:299–302PubMedCrossRef
Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF, Abbate A (2011) The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA 108:19725–19730PubMedPubMedCentralCrossRef
Mills EL, O’Neill LA (2016) Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal. Eur J Immunol 46:13–21PubMedCrossRef
Mooney RE, Linden GJ, Winning L, Linden K, Kee F, McKeown PP, Woodside JV, Patterson CC, McKay GJ (2022) Association of TGFB1 rs1800469 and BCMO1 rs6564851 with coronary heart disease and IL1B rs16944 with all-cause mortality in men from the Northern Ireland PRIME study. PLoS ONE 17:e0273333PubMedPubMedCentralCrossRef
Morton AC, Rothman AM, Greenwood JP, Gunn J, Chase A, Clarke B, Hall AS, Fox K, Foley C, Banya W et al (2015) The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J 36:377–384PubMedCrossRef
Mouton AJ, DeLeon-Pennell KY, Rivera Gonzalez OJ, Flynn ER, Freeman TC, Saucerman JJ, Garrett MR, Ma Y, Harmancey R, Lindsey ML (2018) Mapping macrophage polarization over the myocardial infarction time continuum. Basic Res Cardiol 113:26PubMedPubMedCentralCrossRef
Nakao T, Libby P (2023) IL-6 helps weave the inflammatory web during acute coronary syndromes. J Clin Invest 133
Ning Y, Huang P, Chen G, Xiong Y, Gong Z, Wu C, Xu J, Jiang W, Li X, Tang R et al (2023) Atorvastatin-pretreated mesenchymal stem cell-derived extracellular vesicles promote cardiac repair after myocardial infarction via shifting macrophage polarization by targeting microRNA-139-3p/Stat1 pathway. BMC Med 21:96PubMedPubMedCentralCrossRef
Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, Mukhametshina RT, Kwek XY, Cabrera-Fuentes HA, Hausenloy DJ (2018) Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther 186:73–87PubMedPubMedCentralCrossRef
Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S (1998) Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 98:149–156PubMedCrossRef
Opstad TB, Nordeng J, Pettersen AR, Åkra S, Bratseth V, Zaidi H, Helseth R, Solheim S, Seljeflot I (2022) The NLRP3 genetic variant (rs10754555) reduces the risk of adverse outcome in middle-aged patients with chronic coronary syndrome. J Immunol Res 2022:2366695PubMedPubMedCentralCrossRef
Owyang AM, Maedler K, Gross L, Yin J, Esposito L, Shu L, Jadhav J, Domsgen E, Bergemann J, Lee S et al (2010) XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model. Endocrinology 151:2515–2527PubMedCrossRef
Pan Q, Hui D, Hu C (2022) A variant of IL1B is associated with the risk and blood lipid levels of myocardial infarction in Eastern Chinese individuals. Immunol Invest 51:1162–1169PubMedCrossRef
Papayannopoulos V (2018) Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol 18:134–147PubMedCrossRef
Peng H, Chen L, Deng Y, Liao X, Yang Y (2023) Ginsenoside Rh2 mitigates myocardial damage in acute myocardial infarction by regulating pyroptosis of cardiomyocytes. Clin Exp Hypertens (New York, NY: 1993) 45:2229536
Petzold T, Zhang Z, Ballesteros I, Saleh I, Polzin A, Thienel M, Liu L, Ul Ain Q, Ehreiser V, Weber C et al (2022) Neutrophil “plucking” on megakaryocytes drives platelet production and boosts cardiovascular disease. Immunity 55:2285-2299.e2287PubMedPubMedCentralCrossRef
Prabhu SD, Frangogiannis NG (2016) The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res 119:91–112PubMedPubMedCentralCrossRef
Ramírez J, Cañete JD (2018) Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf 17:727–732PubMedCrossRef
Razin T, Melamed-Book N, Argaman J, Galin I, Lowy Y, Anuka E, Naftali-Shani N, Kandel-Kfir M, Garfinkel BP, Brielle S et al (2021) Interleukin-1α dependent survival of cardiac fibroblasts is associated with StAR/STARD1 expression and improved cardiac remodeling and function after myocardial infarction. J Mol Cell Cardiol 155:125–137PubMedCrossRef
Re F, Sironi M, Muzio M, Matteucci C, Introna M, Orlando S, Penton-Rol G, Dower SK, Sims JE, Colotta F et al (1996) Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface “receptor” with anti-interleukin-1 function. J Exp Med 183:1841–1850PubMedCrossRef
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD et al (2017a) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131PubMedCrossRef
Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ (2017b) Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet (london, England) 390:1833–1842PubMedCrossRef
Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ (2018) Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet (london, England) 391:319–328PubMedCrossRef
Sager HB, Heidt T, Hulsmans M, Dutta P, Courties G, Sebas M, Wojtkiewicz GR, Tricot B, Iwamoto Y, Sun Y et al (2015) Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction. Circulation 132:1880–1890PubMedPubMedCentralCrossRef
Schunk SJ, Triem S, Schmit D, Zewinger S, Sarakpi T, Becker E, Hütter G, Wrublewsky S, Küting F, Hohl M et al (2021) Interleukin-1α is a central regulator of leukocyte-endothelial adhesion in myocardial infarction and in chronic kidney disease. Circulation 144:893–908PubMedCrossRef
Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, MacVittie TJ, Virca GD, Sims JE (2003) The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18:87–96PubMedCrossRef
Su XL, Wang SH, Komal S, Cui LG, Ni RC, Zhang LR, Han SN (2022) The caspase-1 inhibitor VX765 upregulates connexin 43 expression and improves cell-cell communication after myocardial infarction via suppressing the IL-1β/p38 MAPK pathway. Acta Pharmacol Sin 43:2289–2301PubMedPubMedCentralCrossRef
Sun G, Li Y, Ji Z (2019) Up-regulation of MIAT aggravates the atherosclerotic damage in atherosclerosis mice through the activation of PI3K/Akt signaling pathway. Drug Delivery 26:641–649PubMedPubMedCentralCrossRef
Sun Y, Pinto C, Camus S, Duval V, Alayrac P, Zlatanova I, Loyer X, Vilar J, Lemitre M, Levoye A et al (2022) Splenic marginal zone B lymphocytes regulate cardiac remodeling after acute myocardial infarction in mice. J Am Coll Cardiol 79:632–647PubMedCrossRef
Sun JY, Du LJ, Shi XR, Zhang YY, Liu Y, Wang YL, Chen BY, Liu T, Zhu H, Liu Y, et al (2023a) An IL-6/STAT3/MR/FGF21 axis mediates heart-liver cross-talk after myocardial infarction. Sci Adv 9:eade4110
Sun X, Feng Y, Gong C, Bao X, Wei Z, Chang L, Chen H, Xu B (2023b) Hypertension-driven regulatory T-cell perturbations accelerate myocardial ischemia-reperfusion injury. Hypertension (Dallas, Tex: 1979) 80:2046–2058
Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, Wu R, Mellis S, Radin A (2009) The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 68:1613–1617PubMedCrossRef
Tissot AC, Spohn G, Jennings GT, Shamshiev A, Kurrer MO, Windak R, Meier M, Viesti M, Hersberger M, Kündig TM et al (2013) A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis. Eur J Immunol 43:716–722PubMedCrossRef
Toldo S, Abbate A (2018) The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol 15:203–214PubMedCrossRef
Toldo S, Mezzaroma E, McGeough MD, Peña CA, Marchetti C, Sonnino C, Van Tassell BW, Salloum FN, Voelkel NF, Hoffman HM et al (2015) Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart. Cardiovasc Res 105:203–212PubMedCrossRef
Toldo S, Mauro AG, Cutter Z, Abbate A (2018) Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 315:H1553-h1568PubMedPubMedCentralCrossRef
Trankle CR, Canada JM, Cei L, Abouzaki N, Oddi-Erdle C, Kadariya D, Christopher S, Viscusi M, Del Buono M, Kontos MC et al (2018) Usefulness of canakinumab to improve exercise capacity in patients with long-term systolic heart failure and elevated C-reactive protein. Am J Cardiol 122:1366–1370PubMedPubMedCentralCrossRef
Wang Y, Tan J, Yin J, Hu H, Shi Y, Wang Y, Xue M, Li X, Liu J, Li Y et al (2019a) Targeting blockade of nuclear factor-κB in the hypothalamus paraventricular nucleus to prevent cardiac sympathetic hyperinnervation post myocardial infarction. Neurosci Lett 707:134319PubMedCrossRef
Wang Y, Yin J, Wang C, Hu H, Li X, Xue M, Liu J, Cheng W, Wang Y, Li Y et al (2019b) Microglial Mincle receptor in the PVN contributes to sympathetic hyperactivity in acute myocardial infarction rat. J Cell Mol Med 23:112–125PubMedCrossRef
Wang Z, Kun Y, Lei Z, Dawei W, Lin P, Jibo W (2021) LncRNA MIAT downregulates IL-1β, TNF-ɑ to suppress macrophage inflammation but is suppressed by ATP-induced NLRP3 inflammasome activation. Cell Cycle (georgetown, Tex) 20:194–203PubMedCrossRef
Wang C, Zhang M, Yan J, Wang R, Wang Z, Sun X, Dong S (2023a) Chemokine-like receptor 1 deficiency impedes macrophage phenotypic transformation and cardiac repair after myocardial infarction. Int J Cardiol 372:6–14PubMedCrossRef
Wang D, Hu Y, Zhang L, Cai H, Wang Y, Zhang Y (2023b) Dual delivery of an NF-κB inhibitor and IL-10 through supramolecular hydrogels polarizes macrophages and promotes cardiac repair after myocardial infarction. Acta Biomater 164:111–123PubMedCrossRef
Wang Q, Wang T, Lio C, Yu X, Chen X, Liu L, Wu Y, Huang H, Qing L, Luo P (2023c) Surface hydrolysis-designed AuNPs-zwitterionic-glucose as a novel tool for targeting macrophage visualization and delivery into infarcted hearts. J Controll Release 356:678–690CrossRef
Wei X, Lv Y, Yang C, Gao R, Zou S, Xu Y (2023) Bufalin reduces myocardial infarction-induced myocardial fibrosis and improves cardiac function by inhibiting the NLRP3/IL-1β signalling pathway. Clin Exp Pharmacol Physiol 50:688–697PubMedCrossRef
Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y, Voronov E, Dinarello CA, Apte RN (2004) The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA 101:2434–2439PubMedPubMedCentralCrossRef
Woxholt S, Ueland T, Aukrust P, Anstensrud AK, Broch K, Tøllefsen IM, Ryan L, Bendz B, Hopp E, Kløw NE, et al (2023) Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab. Open Heart 10
Xia N, Lu Y, Gu M, Li N, Liu M, Jiao J, Zhu Z, Li J, Li D, Tang T et al (2020) A unique population of regulatory T cells in heart potentiates cardiac protection from myocardial infarction. Circulation 142:1956–1973PubMedCrossRef
Yan X, Anzai A, Katsumata Y, Matsuhashi T, Ito K, Endo J, Yamamoto T, Takeshima A, Shinmura K, Shen W et al (2013) Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. J Mol Cell Cardiol 62:24–35PubMedCrossRef
Yin J, Wang Y, Hu H, Li X, Xue M, Cheng W, Wang Y, Li X, Yang N, Shi Y et al (2017) P2X(7) receptor inhibition attenuated sympathetic nerve sprouting after myocardial infarction via the NLRP3/IL-1β pathway. J Cell Mol Med 21:2695–2710PubMedPubMedCentralCrossRef
Zandi E, Chen Y, Karin M (1998) Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science (new York, NY) 281:1360–1363CrossRef
Zhang W, Lavine KJ, Epelman S, Evans SA, Weinheimer CJ, Barger PM, Mann DL (2015) Necrotic myocardial cells release damage-associated molecular patterns that provoke fibroblast activation in vitro and trigger myocardial inflammation and fibrosis in vivo. J Am Heart Assoc 4:e001993PubMedPubMedCentralCrossRef
Zhang J, Huang L, Shi X, Yang L, Hua F, Ma J, Zhu W, Liu X, Xuan R, Shen Y et al (2020) Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway. Aging 12:24270–24287PubMedPubMedCentralCrossRef
Zhang J, Hao W, Zhang J, Li T, Ma Y, Wang Y, Li X, Cui W, Du J (2023) CXCL16 promotes Ly6Chigh monocyte infiltration and impairs heart function after acute myocardial infarction. J Immunol (Baltimore, MD: 1950) 210:820–831
Zhao Z, Du S, Shen S, Wang L (2020) microRNA-132 inhibits cardiomyocyte apoptosis and myocardial remodeling in myocardial infarction by targeting IL-1β. J Cell Physiol 235:2710–2721PubMedCrossRef
Zhaolin Z, Guohua L, Shiyuan W, Zuo W (2019) Role of pyroptosis in cardiovascular disease. Cell Prolif 52:e12563PubMedCrossRef
Zheng Y, Humphry M, Maguire JJ, Bennett MR, Clarke MC (2013) Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1α, controlling necrosis-induced sterile inflammation. Immunity 38:285–295PubMedPubMedCentralCrossRef
Zheng W, Zhou T, Zhang Y, Ding J, Xie J, Wang S, Wang Z, Wang K, Shen L, Zhu Y et al (2023) Simplified α(2)-macroglobulin as a TNF-α inhibitor for inflammation alleviation in osteoarthritis and myocardial infarction therapy. Biomaterials 301:122247PubMedCrossRef
Zhou X, Zhang C, Wu X, Hu X, Zhang Y, Wang X, Zheng L, Gao P, Du J, Zheng W et al (2022) Dusp6 deficiency attenuates neutrophil-mediated cardiac damage in the acute inflammatory phase of myocardial infarction. Nat Commun 13:6672PubMedPubMedCentralCrossRef
Zhuang R, Meng Q, Ma X, Shi S, Gong S, Liu J, Li M, Gu W, Li D, Zhang X et al (2022) CD4(+)FoxP3(+)CD73(+) regulatory T cell promotes cardiac healing post-myocardial infarction. Theranostics 12:2707–2721PubMedPubMedCentralCrossRef
Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guérin C, Vilar J, Caligiuri G, Tsiantoulas D, Laurans L et al (2013) B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med 19:1273–1280PubMedPubMedCentralCrossRef
Zuurbier CJ, Abbate A, Cabrera-Fuentes HA, Cohen MV, Collino M, De Kleijn DPV, Downey JM, Pagliaro P, Preissner KT, Takahashi M et al (2019) Innate immunity as a target for acute cardioprotection. Cardiovasc Res 115:1131–1142PubMedCrossRef
Metadata
Title
IL-1 signaling pathway, an important target for inflammation surrounding in myocardial infarction
Authors
Jianwu Huang
Wenlong Kuang
Zihua Zhou
Publication date
27-04-2024
Publisher
Springer International Publishing
Published in
Inflammopharmacology
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-024-01481-4